Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
Sponsor: Tandem Diabetes Care, Inc.
Summary
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.
Key Details
Gender
All
Age Range
6 Years - Any
Study Type
OBSERVATIONAL
Enrollment
350
Start Date
2026-03-03
Completion Date
2027-12
Last Updated
2026-04-02
Healthy Volunteers
No
Conditions
Interventions
t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
Participants enrolled in the study will start use of the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with Dexcom G6 or Dexcom G7, and be followed for 12 months.
Locations (13)
CH Agen-Nérac
Agen, France
CHU Lyon HFME
Bron, France
Centre du Diabète - Diab-e-Care Hospices Civils de Lyon (HCL)
Lyon, France
Hôpital Européen (APHM)
Marseille, France
CHR Metz-Thionville
Metz, France
CHU de Montpellier
Montpellier, France
Clinique Saint Jean de Védas
Montpellier, France
Hôpital Lariboisière
Paris, France
GH Paris Saint-Joseph
Paris, France
MSP Les Belles Fleurs
Saint-Cyr-sur-Loire, France
Clinique Pasteur Toulouse
Toulouse, France
CHU Toulouse
Toulouse, France
CHU Tours
Tours, France